Cargando…
CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies
Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is a devastating event occurring in ~ 5% of patients treated with R-CHOP. We hypothesized that adding lenalidomide to R-CHOP (R2CHOP) may decrease the risk of CNS relapse. We analyzed records for patients with DLBCL from t...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018787/ https://www.ncbi.nlm.nih.gov/pubmed/29946110 http://dx.doi.org/10.1038/s41408-018-0097-0 |
_version_ | 1783335021037223936 |
---|---|
author | Ayed, Ayed O. Chiappella, Annalisa Pederson, Levi Laplant, Betsy R. Congiu, Angela Giovanna Gaidano, Gianluca Spina, Michele Re, Alessandro Cavallo, Federica Musuraca, Gerardo Macon, William R. Witzig, Thomas Vitolo, Umberto Nowakowski, Grzegorz S. |
author_facet | Ayed, Ayed O. Chiappella, Annalisa Pederson, Levi Laplant, Betsy R. Congiu, Angela Giovanna Gaidano, Gianluca Spina, Michele Re, Alessandro Cavallo, Federica Musuraca, Gerardo Macon, William R. Witzig, Thomas Vitolo, Umberto Nowakowski, Grzegorz S. |
author_sort | Ayed, Ayed O. |
collection | PubMed |
description | Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is a devastating event occurring in ~ 5% of patients treated with R-CHOP. We hypothesized that adding lenalidomide to R-CHOP (R2CHOP) may decrease the risk of CNS relapse. We analyzed records for patients with DLBCL from two R2CHOP trials. We assessed variables pertinent to the CNS-International Prognostic Index (CNS-IPI) scoring system and classified patients into groups of low, intermediate, and high risk of CNS relapse. The 2-year CNS relapse rate for each risk group was estimated using the Kaplan–Meier method and compared with reported rates in cohorts treated with contemporary chemoimmunotherapy. A total of 136 patients were included. Mean age was 65 and median follow-up was 48.2 months. 10.3, 71.3, and 18.4% of patients were classified into low, intermediate, and high-risk CNS-IPI groups, respectively. Only one of 136 patients developed CNS relapse, corresponding to an incidence of 0.7% and an estimated 2-year CNS relapse rate of 0.9% for the entire R2CHOP cohort. The estimated 2-year CNS relapse rates for the low, intermediate, and high-risk groups were 0, 0, and 5.0%, respectively. Frontline therapy with R2CHOP in patients with DLBCL is associated with a lower-than-expected rate of CNS relapse. |
format | Online Article Text |
id | pubmed-6018787 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-60187872018-06-27 CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies Ayed, Ayed O. Chiappella, Annalisa Pederson, Levi Laplant, Betsy R. Congiu, Angela Giovanna Gaidano, Gianluca Spina, Michele Re, Alessandro Cavallo, Federica Musuraca, Gerardo Macon, William R. Witzig, Thomas Vitolo, Umberto Nowakowski, Grzegorz S. Blood Cancer J Article Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is a devastating event occurring in ~ 5% of patients treated with R-CHOP. We hypothesized that adding lenalidomide to R-CHOP (R2CHOP) may decrease the risk of CNS relapse. We analyzed records for patients with DLBCL from two R2CHOP trials. We assessed variables pertinent to the CNS-International Prognostic Index (CNS-IPI) scoring system and classified patients into groups of low, intermediate, and high risk of CNS relapse. The 2-year CNS relapse rate for each risk group was estimated using the Kaplan–Meier method and compared with reported rates in cohorts treated with contemporary chemoimmunotherapy. A total of 136 patients were included. Mean age was 65 and median follow-up was 48.2 months. 10.3, 71.3, and 18.4% of patients were classified into low, intermediate, and high-risk CNS-IPI groups, respectively. Only one of 136 patients developed CNS relapse, corresponding to an incidence of 0.7% and an estimated 2-year CNS relapse rate of 0.9% for the entire R2CHOP cohort. The estimated 2-year CNS relapse rates for the low, intermediate, and high-risk groups were 0, 0, and 5.0%, respectively. Frontline therapy with R2CHOP in patients with DLBCL is associated with a lower-than-expected rate of CNS relapse. Nature Publishing Group UK 2018-06-26 /pmc/articles/PMC6018787/ /pubmed/29946110 http://dx.doi.org/10.1038/s41408-018-0097-0 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Ayed, Ayed O. Chiappella, Annalisa Pederson, Levi Laplant, Betsy R. Congiu, Angela Giovanna Gaidano, Gianluca Spina, Michele Re, Alessandro Cavallo, Federica Musuraca, Gerardo Macon, William R. Witzig, Thomas Vitolo, Umberto Nowakowski, Grzegorz S. CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies |
title | CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies |
title_full | CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies |
title_fullStr | CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies |
title_full_unstemmed | CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies |
title_short | CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies |
title_sort | cns relapse in patients with dlbcl treated with lenalidomide plus r-chop (r2chop): analysis from two phase 2 studies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018787/ https://www.ncbi.nlm.nih.gov/pubmed/29946110 http://dx.doi.org/10.1038/s41408-018-0097-0 |
work_keys_str_mv | AT ayedayedo cnsrelapseinpatientswithdlbcltreatedwithlenalidomideplusrchopr2chopanalysisfromtwophase2studies AT chiappellaannalisa cnsrelapseinpatientswithdlbcltreatedwithlenalidomideplusrchopr2chopanalysisfromtwophase2studies AT pedersonlevi cnsrelapseinpatientswithdlbcltreatedwithlenalidomideplusrchopr2chopanalysisfromtwophase2studies AT laplantbetsyr cnsrelapseinpatientswithdlbcltreatedwithlenalidomideplusrchopr2chopanalysisfromtwophase2studies AT congiuangelagiovanna cnsrelapseinpatientswithdlbcltreatedwithlenalidomideplusrchopr2chopanalysisfromtwophase2studies AT gaidanogianluca cnsrelapseinpatientswithdlbcltreatedwithlenalidomideplusrchopr2chopanalysisfromtwophase2studies AT spinamichele cnsrelapseinpatientswithdlbcltreatedwithlenalidomideplusrchopr2chopanalysisfromtwophase2studies AT realessandro cnsrelapseinpatientswithdlbcltreatedwithlenalidomideplusrchopr2chopanalysisfromtwophase2studies AT cavallofederica cnsrelapseinpatientswithdlbcltreatedwithlenalidomideplusrchopr2chopanalysisfromtwophase2studies AT musuracagerardo cnsrelapseinpatientswithdlbcltreatedwithlenalidomideplusrchopr2chopanalysisfromtwophase2studies AT maconwilliamr cnsrelapseinpatientswithdlbcltreatedwithlenalidomideplusrchopr2chopanalysisfromtwophase2studies AT witzigthomas cnsrelapseinpatientswithdlbcltreatedwithlenalidomideplusrchopr2chopanalysisfromtwophase2studies AT vitoloumberto cnsrelapseinpatientswithdlbcltreatedwithlenalidomideplusrchopr2chopanalysisfromtwophase2studies AT nowakowskigrzegorzs cnsrelapseinpatientswithdlbcltreatedwithlenalidomideplusrchopr2chopanalysisfromtwophase2studies |